Page 279 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 279
P0910 NO EVIDENCE OF PHARMACOKINETIC DRUG-DRUG ePOSTERS
YI P0911 INTERACTION IN HEALTHY SUBJECTS BETWEEN
YI P0912 COADMINISTERED GRAZOPREVIR (MK-5172)/ ELBASVIR
YI P0913 (MK-8742) AND SOFOSBUVIR
William L. Marshall*, Wendy W. Yeh, Daria Stypinski, Patrice Auger,
Crystal Bethel-Brown, Luzelena Caro, Patricia Jumes, Xiaobi Huang,
Zifang Guo, Monika Martinho, H-P Feng, Danielle Armas, John Brejda,
Marian Iwamoto, Joan R. Butterton, The United States
CHARACTERIZATION OF CLINICAL PREDICTORS
OF NATURALLY OCCURRING NS3/NS4A PROTEASE
POLYMORPHISM IN GENOTYPE 1 HEPATITIS C VIRUS
INFECTED PATIENTS
Gaspar Lisboa Neto*, Caroline Noble, João Renato R. Pinho,
Fernanda M. Malta, Michele S. Gomes-Gouvêa, Monica V. Alvarado-
Mora, Mariliza H. Silva, Andrea G. Leite, Leonora Z. Piccoli,
Flair José Carrilho, Maria Cássia Mendes-Correa, Brazil
EARLY-PHASE HCV KINETICS AND ROLE OF PRE-
EXISTING RESISTANCE IN CIRRHOTIC OR INTERFERON-
INSENSITIVE PATIENTS ON DACLATASVIR PLUS
ASUNAPREVIR
Valeria Cento*, Vincenza Calvaruso, Simona Marenco, Roberta Alfieri,
Marianna Aragri, Francesco Paolo Antonucci, Velia Chiara Di Maio,
Salvatore Petta, Alessandra Mazzola, Luciano Milanesi,
Antonino Picciotto, Francesca Ceccherini-Silberstein, Antonio Craxì,
Carlo Federico Perno, Italy
INTERACTIONS STUDY OF HCV NSB5 POLYMERASE
INHIBITORS WITH NSB5 NON-STRUCTURED PROTEINS
TOWARD BETTER DESIGN OF NEW INHIBITORS BASED
ON MOLECULAR DOCKING AND PHARMACOPHORE
METHODS
Mahdi Shahmohammadi Aghbolagh*, Eslam Pourbasheer,
Reza Aalizadeh, Sweden
Vienna, Austria • April 22–26, 2015 279
YI P0911 INTERACTION IN HEALTHY SUBJECTS BETWEEN
YI P0912 COADMINISTERED GRAZOPREVIR (MK-5172)/ ELBASVIR
YI P0913 (MK-8742) AND SOFOSBUVIR
William L. Marshall*, Wendy W. Yeh, Daria Stypinski, Patrice Auger,
Crystal Bethel-Brown, Luzelena Caro, Patricia Jumes, Xiaobi Huang,
Zifang Guo, Monika Martinho, H-P Feng, Danielle Armas, John Brejda,
Marian Iwamoto, Joan R. Butterton, The United States
CHARACTERIZATION OF CLINICAL PREDICTORS
OF NATURALLY OCCURRING NS3/NS4A PROTEASE
POLYMORPHISM IN GENOTYPE 1 HEPATITIS C VIRUS
INFECTED PATIENTS
Gaspar Lisboa Neto*, Caroline Noble, João Renato R. Pinho,
Fernanda M. Malta, Michele S. Gomes-Gouvêa, Monica V. Alvarado-
Mora, Mariliza H. Silva, Andrea G. Leite, Leonora Z. Piccoli,
Flair José Carrilho, Maria Cássia Mendes-Correa, Brazil
EARLY-PHASE HCV KINETICS AND ROLE OF PRE-
EXISTING RESISTANCE IN CIRRHOTIC OR INTERFERON-
INSENSITIVE PATIENTS ON DACLATASVIR PLUS
ASUNAPREVIR
Valeria Cento*, Vincenza Calvaruso, Simona Marenco, Roberta Alfieri,
Marianna Aragri, Francesco Paolo Antonucci, Velia Chiara Di Maio,
Salvatore Petta, Alessandra Mazzola, Luciano Milanesi,
Antonino Picciotto, Francesca Ceccherini-Silberstein, Antonio Craxì,
Carlo Federico Perno, Italy
INTERACTIONS STUDY OF HCV NSB5 POLYMERASE
INHIBITORS WITH NSB5 NON-STRUCTURED PROTEINS
TOWARD BETTER DESIGN OF NEW INHIBITORS BASED
ON MOLECULAR DOCKING AND PHARMACOPHORE
METHODS
Mahdi Shahmohammadi Aghbolagh*, Eslam Pourbasheer,
Reza Aalizadeh, Sweden
Vienna, Austria • April 22–26, 2015 279
